March 21, 2025 |
Pharma companies must balance HCP access and MHRA/ABPI compliance by preventing public search indexing of promotional prescription medicine content.

Pharmaceutical companies are increasingly using online platforms to share important information with healthcare professionals (HCPs). While this offers a modern and efficient way to communicate, it also raises significant compliance challenges. One key question that companies need to address is whether having promotional materials—including Prescribing Information (PI) pages—indexed by search engines could lead to regulatory breaches.
In the UK, regulations from the Medicines and Healthcare products Regulatory Agency (MHRA) and the Association of the British Pharmaceutical Industry (ABPI) are clear: the promotion of prescription-only medicines (POMs) to the general public is strictly prohibited. The ABPI Code of Practice explicitly states that promotional content for prescription medicines must not be accessible to the public. But what does this mean for online promotional materials that can be discovered via search engines?
When promotional pages are indexed by search engines like Google, there is a risk that members of the general public could find them in search results. Even if the actual content is behind an HCP confirmation wall, search engine snippets, page titles, or meta descriptions may reveal information that could be interpreted as promotional. This kind of exposure could potentially breach MHRA and ABPI guidelines, resulting in significant compliance risks for the company.
Common Compliance Risks
One major issue with indexed promotional materials is public exposure. Search snippets or meta descriptions can inadvertently disclose medicine names, uses, or even promotional phrases. Even if these details seem minimal, they may still be viewed as promotion, and this is where companies could find themselves in breach of regulations.
Another risk lies in the limitations of access controls. Simply requiring HCPs to confirm their credentials after clicking on a search result doesn’t fully eliminate the risk. The information visible in search engine results might still be interpreted as advertising POMs to the public, which is against UK regulations.
Best Practices for Compliance
To minimise these risks, pharmaceutical companies should implement a few key strategies:
Balancing Accessibility with Compliance
Maintaining the right balance between making information easily accessible to HCPs while ensuring compliance with MHRA and ABPI guidelines can be a challenging aspect of pharma SEO. Utilising secure, direct communication channels, or professional platforms specifically designed for HCPs, can help mitigate compliance risks while still providing essential information to the right audience.
For a more detailed exploration of this topic and practical strategies to stay compliant, check out our full article: Compliance Risks of Indexing Promotional Pharmaceutical Content for SEO: Key Insights on MHRA and ABPI Guidelines
This content was provided by Genetic Digital
Company Details
Latest Content from Genetic Digital
Pharma companies must balance HCP access and MHRA/ABPI compliance by preventing public search indexing of promotional prescription medicine content.
Pharma companion apps are transforming healthcare by offering support beyond traditional treatments, enhancing patient engagement and outcomes. From medication reminders to symptom tracking, these apps provide valuable tools for both…
